Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment

Author:

Tervonen Tommi1,Whichello Chiara2,Law Ernest3,Mauer Jonathan3,Mitra Debanjali3,Trapali Myrto2,Krucien Nicolas2,Hauber Brett3ORCID

Affiliation:

1. Kielo Research Zug Switzerland

2. Evidera Inc. London UK

3. Pfizer Inc. New York City New York USA

Abstract

AbstractPRODUCTS with janus kinase (JAK) inhibition have been shown to promote hair regrowth in patients with alopecia areata (AA). To guide drug‐approval and treatment decisions, it is important to understand patients' willingness to accept the potential risks of JAK inhibition in exchange for potential benefits. We quantified the treatment preferences of adult (≥18 years) and adolescent patients (12–17 years) with AA in the US and Europe to determine the trade‐offs they are willing to make between benefits and risks. Preferences for oral AA treatment attributes were elicited using a discrete choice experiment consisting of 12 tasks in which patients chose between two hypothetical treatment alternatives and no treatment. Benefits included the probability of 80%–100% scalp hair regrowth (Severity of Alopecia Tool score ≤ 20) and achieving moderate‐to‐normal eyebrow and eyelash hair. Treatment‐related risks included 3‐year probabilities of serious infection, cancer, and blood clots. Preference estimates were used to calculate the maximum level of each risk that patients were willing to accept for increases in treatment benefits. The most important attribute to both adults (n = 201) and adolescents (n = 120) was a 50% probability of achieving hair regrowth on most or all the scalp; however, adolescents placed greater relative importance on this attribute than did adults. Adults were averse to the risks of serious infection, cancer, and blood clots, whereas adolescents were averse to the risk of cancer. For a 20% increase in the probability of 80%–100% scalp hair regrowth, adults were willing to accept a mean (95% confidence interval) 3‐year risk of serious infection, cancer, and blood clots of 7.4% (5.5–9.3), 2.5% (1.9–3.1), and 9.3% (6.4–12.2). Adolescents were willing to accept a 3‐year risk of cancer of 3.3% (2.4–4.2). Patients with AA in the US and Europe are willing to accept substantial risks to obtain an effective treatment.

Funder

Pfizer

Publisher

Wiley

Subject

Dermatology,General Medicine

Reference37 articles.

1. Epidemiology and burden of alopecia areata: a systematic review;Villasante Fricke AC;Clin Cosmet Investig Dermatol,2015

2. Overview of Alopecia Areata

3. Cumulative life course impairment of alopecia areata

4. Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications;Shalabi MMK;Skin Therapy Lett,2022

5. Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3